Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MGAM | O43451 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 3/20 | 0.37 |
| ▸ | SI | P14410 | 3/20 | 0.37 |
| ▸ | MGAM2 | Q2M2H8 | 3/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.36 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethoxycarbonyl Group SCHEMBL28828682 | 0.82 | DRD4 (0.34) | EGFRDRD4DRD3L3MBTL1PDE3B | |
| SCHEMBL8404376 | 0.79 | CYP2A6 (0.39) | PDE3BPDE3AATMCYP2A6CYP1A2 | |
| SCHEMBL2917596 | 0.79 | NOS1 (0.39) | EGFRL3MBTL1GAACYP2A6CYP1A2 | |
| SCHEMBL1634276 | 0.76 | METAP2 (0.48) | GAACYP1A2ADRA1AALDH1A1 | |
| SCHEMBL2916502 | 0.76 | FGFR1 (0.50) | EGFRALDH1A1 | |
| SCHEMBL23003201 | 0.76 | EGFR (0.38) | EGFRL3MBTL1GAARPS6KA5ALDH1A1 | |
| SCHEMBL27351676 | 0.76 | KDM4E (0.35) | EGFRCYP2A6CYP1A2RPS6KA5ALDH1A1 | |
| SCHEMBL31114211 | 0.76 | BACE1 (0.46) | EGFRCYP1A2RPS6KA5ALDH1A1AR | |
| SCHEMBL19466048 | 0.76 | PARP1 (0.37) | L3MBTL1GAAPDE3BPDE3AATM | |
| SCHEMBL559708 | 0.76 | BACE1 (0.46) | EGFRCYP1A2RPS6KA5ALDH1A1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105283454-B | Quinazoline and azepine quinazoline as RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/MTOR access double inhibitor | ASANA BIOSCIENCES, LLC (US) | 2019-10-29 | — | — | CN | disclosed |
| CN-108699032-A | Polycyclic T L R7/8 antagonists and their use in treating immune disorders | 默克专利有限公司 | 2018-10-23 | — | — | CN | disclosed |
| CN-105473574-B | Somatostatin receptor subtype 4(SSTR4) agonists | 森特克森治疗公司 | 2018-02-13 | — | — | CN | disclosed |
| CN-105025899-B | Having a2AHeterobicyclically substituted- [1,2,4 ] antagonists]Triazolo [1,5-c]Quinazoline-5-amine compounds | 默沙东公司 | 2017-08-18 | — | — | CN | disclosed |
| CN-105473574-A | Novel somatostatin receptor subtype 4(SSTR4) agonists | BOEHRINGER INGELHEIM INT | 2016-04-06 | — | — | CN | disclosed |
| CN-105452238-A | Bicyclic derivatives containing a pyrimidine ring and process for preparing the same | YUHAN CORP | 2016-03-30 | — | — | CN | disclosed |
| CN-105283454-A | Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/MTOR pathways | ASANA BIOSCIENCES LLC | 2016-01-27 | — | — | CN | disclosed |
| CN-105025899-A | Having a2AHeterobicyclically substituted- [1 ] with antagonist properties | MERCK SHARP & DOHME | 2015-11-04 | — | — | CN | disclosed |
| CN-103724282-B | Synthesis method of quinazoline derivatives as pharmaceutical intermediate | YU HAIBO | 2015-07-08 | — | — | CN | disclosed |
| CN-104610169-A | Quinazoline-containing thioether substituted pentadiene ketone derivatives, and preparation method and application thereof | UNIV GUIZHOU | 2015-05-13 | — | — | CN | disclosed |
| EP-2432779-A1 | BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES | Exelixis, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20100311965-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | CARNA BIOSCIENCES INC. (JP) | 2010-12-09 | — | — | US | disclosed |
| US-20100311965-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | CARNA BIOSCIENCES INC. (JP) | 2010-12-09 | — | — | US | disclosed |
| US-20100311965-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | CARNA BIOSCIENCES INC. (JP) | 2010-12-09 | — | — | US | disclosed |
| WO-2010135524-A1 | BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES | EXELIXIS, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| EP-2226315-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | Carna Biosciences Inc. (JP) | 2010-09-08 | — | — | EP | disclosed |
| EP-2226315-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | Carna Biosciences Inc. (JP) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009084695-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | CARNA BIOSCIENCES INC. (JP) | 2009-07-09 | — | — | WO | disclosed |
| CN-1033380-A | Compound | SMITHKLINE BECKMAN INTERCREDIT (NL) | 1989-06-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311965-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | DSTYK, ABL1, EEF2K | EGFR 479/4885DRD4 3928/4885DRD3 3307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.